In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...
Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...
Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...
Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche. | Amid a steady advance of kidney-focused label expansions, ...
Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results